Target

IL-23

Interleukin-23

Also: IL-23p19

18open trials
28trials in total
136publications
0researchers

Diseases

The last 24 months

New trials, publications, preprints and grants on this target, month by month.

TrialsPublicationsPreprintsGrants

Publication
Oral IL-23 receptor blockade shows promise in ulcerative colitis.
2 Nov 2026· Nature reviews. Gastroenterology & hepatology· PUBMED
Publication
Targeting the IL-23-IL-23R Interface with Small Molecules: Challenges, Opportunities, and Emerging Strategies.
30 Oct 2026· Mini reviews in medicinal chemistry· PUBMED
Publication
Targeting the IL-23 pathway in inflammatory bowel disease: from cytokine inhibition to oral IL-23 receptor blockade.
30 Oct 2026· eGastroenterology· PUBMED
Publication
Altered IL-23/IL-17A immune axis in Parkinson's disease: An exploratory analysis.
22 Oct 2026· Parkinsonism & related disorders· PUBMED
Publication
Potential association between IL-12/23, IL-23, and IL-17 inhibitors and skin cancer: a pharmacovigilance study based on the FAERS database.
22 Oct 2026· Frontiers in pharmacology· PUBMED
Publication
Safety profile of IL-23 inhibitors from the perspective of physicians and pharmacists: A retrospective real-world pharmacovigilance observational study based on the FAERS database.
19 Oct 2026· Science progress· PUBMED
Publication
Targeting IL-12 and IL-23 in immune-related adverse events from checkpoint inhibitors: current evidence and future directions.
15 Oct 2026· European journal of cancer (Oxford, England : 1990)· PUBMED
Publication
Comparative Effects of IL-17 and IL-23 Inhibitors on Lipid Profiles and Lipid-Derived Atherogenic Indices in Patients with Psoriasis.
13 Oct 2026· Pharmaceuticals (Basel, Switzerland)· PUBMED
Publication
Changes in the FIB-4 index with IL-23 vs IL-17 inhibitors in psoriasis: a retrospective cohort study.
13 Oct 2026· Expert opinion on biological therapy· PUBMED
Publication
Impact of IL-17A and IL-23p19 Inhibitors on Psychiatric Outcomes and Inflammation in Psoriasis.
12 Oct 2026· Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG· PUBMED
Trial
Risankizumab for Refractory Perianal Fistulizing Crohn's Disease
1 Oct 2026· PHASE4 · RECRUITING· CTGOV
Publication
Adjusted Comparative Treatment Persistence of IL-23p19 Versus IL-17 Pathway Inhibitors in Adults With Plaque Psoriasis: A Systematic Review and Exploratory Meta-analysis of Real-World Time-to-Discontinuation Estimates.
1 Oct 2026· Cureus· PUBMED
Publication
IL-23 and monocyte interactions redirect human Th17.1 cells to an IL-17AhighIFN-γhigh potentially pathogenic profile.
30 Sept 2026· Frontiers in immunology· PUBMED
Publication
Clinical case series: Emergence of psoriatic arthritis during biologic IL-23 pathway inhibition therapy for psoriasis.
30 Sept 2026· Frontiers in medicine· PUBMED
Publication
A Case of Genital-Predominant Inverse Psoriasis With Psoriatic Arthritis Treated With Sequential IL-23/IL-17-Targeted Biologic Therapy.
30 Sept 2026· The Journal of dermatology· PUBMED
Publication
Targeting IL-23p19 in Inflammatory Bowel Disease: The Road Ahead.
30 Sept 2026· Journal of inflammation research· PUBMED
Publication
IL-23-engineered oncolytic vaccinia virus enhances pancreatic cancer control through inflammasome-driven Th17-skewed CD4+ T-cell responses.
28 Sept 2026· Journal for immunotherapy of cancer· PUBMED
Publication
Targeted oral peptide therapy for inflammatory bowel disease: focus on the IL-23 receptor antagonist icotrokinra.
28 Sept 2026· Expert opinion on emerging drugs· PUBMED
Publication
Obesity modifies response to IL-23p19 inhibitors in psoriasis: Systematic review and meta-analysis.
21 Sept 2026· Journal of the European Academy of Dermatology and Venereology : JEADV· PUBMED
Publication
Tangeretin alleviates psoriasis through inhibition of the IL-23/IL-23R signaling pathway.
19 Sept 2026· International immunopharmacology· PUBMED
Publication
From IL-23/IL-17 to GM-CSF: how is the immuno-inflammatory continuum reshaped in spondyloarthritis?
17 Sept 2026· Frontiers in immunology· PUBMED
Publication
Unravelling the role of the non-coding RNAs PVT1/miR-181a in orchestrating IL-23/RORγt and FOXP3/IL-10 axes in thrombocytopenia associated with systemic lupus erythematosus: insights into the clinical paradox of antiphospholipid syndrome.
15 Sept 2026· Molecular biology reports· PUBMED
Trial
Clinical Trial of an IL-23 Inhibitor for Immune Activation in Clinical Trial of an IL-23 Inhibitor for Immune Activation in People With Schizophrenia
1 Sept 2026· PHASE4 · NOT_YET_RECRUITING· CTGOV
Publication
The IL-23/-17 Axis in PsA: What Have We Learned in the Last 20 Years?
1 Sept 2026· Mediterranean journal of rheumatology· PUBMED
Publication
The promise of oral IL-23 blockade: One-year control of high-impact site psoriasis.
1 Sept 2026· Journal of the European Academy of Dermatology and Venereology : JEADV· PUBMED
Publication
Scopolamine ameliorates psoriasis by blocking M1 receptor-mediated IL-23 production in dendritic cells.
29 Aug 2026· Journal of immunology (Baltimore, Md. : 1950)· PUBMED
Publication
Efficacy, safety and outcome of selective IL-23 inhibitor risankizumab in induction and maintenance of CD and ulcerative colitis: A systematic review.
28 Aug 2026· Medicine· PUBMED
Publication
Pharmacokinetics of IL-23p19 Inhibitors: A Systematic Review Across Immune-Mediated Inflammatory Diseases.
22 Aug 2026· Clinical pharmacokinetics· PUBMED
Publication
Integrating Genetic Modifier Genotype With Serum Proteomics in Duchenne Muscular Dystrophy Clinical Trials Links LTBP4 Genetic Modifier to IL-23/CD93 Pathways in Muscle.
18 Aug 2026· American journal of medical genetics. Part A· PUBMED
Publication
IL-23 promotes PD-L1 expression and tumor immune evasion via METTL16 pathway.
15 Aug 2026· American journal of cancer research· PUBMED

Who works on it

Researchers who published on this target. Leave out your own co-author circle to find people you do not know yet.

No published researcher profile on this target yet.

We look for a fixed list of target names in titles, keywords, intervention names and MeSH terms. A mention does not prove that the work is aimed at that target.

Report an error